Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661490 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
A Phase 2 study of Norovirus, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 320
- Enrollment target
- 10
- Study locations
NCT02661490: Completed Phase 2 study of Norovirus, sponsored by Takeda.
NCT02661490 is a Phase 2 study of Norovirus that has completed, run by Takeda. The registered enrollment target is 320 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02661490, a Phase 2 study of Norovirus, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 320 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to further develop a formulation and dose regimen of the norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe in an elderly population aged 60 years and above.
Conditions Studied
Interventions
- BIOLOGICAL Norovirus GI.1/GII.4 Bivalent VLP Vaccine
- DRUG 0.9% sodium chloride (saline)
Study Locations (10)
New York
- Regional Clinical Research Inc. - Endwell
- University of Rochester - Rochester
Alabama
- Simon Williamson Clinic - Birmingham
Arizona
- Fountain Hills Family Practice, P.C. - Fountain Hills
Colorado
- Southwest Family Medicine - Littleton
Florida
- Miami Research Associates - Miami
Kansas
- Johnson County Clin-Trials - Lenexa
Missouri
- St. Louis University, School of Medicine - St Louis
Ohio
- Cincinnati Childrens Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2017-09-29 |
| Phase | Phase 2 |
What the finished NCT02661490 record still lists
NCT02661490 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 1 condition, with Norovirus appearing as the primary indexed condition, and to 2 interventions - of which Norovirus GI.1/GII.4 Bivalent VLP Vaccine is the first listed.
NCT02661490 lists 10 locations in 9 states (New York, Alabama, Arizona).
Frequently Asked Questions
What is clinical trial NCT02661490 about?
NCT02661490 is a clinical study titled "Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population". The purpose of this study is to further develop a formulation and dose regimen of the norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe in an elderly population aged 60 years and above.
What is the current status of trial NCT02661490?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 320 participants. The study started on 2016-02-01. Estimated completion is 2017-09-29.
What conditions does trial NCT02661490 study?
This clinical trial studies the following conditions: Norovirus.
What interventions are being tested in trial NCT02661490?
The interventions under investigation include: Norovirus GI.1/GII.4 Bivalent VLP Vaccine (BIOLOGICAL), 0.9% sodium chloride (saline) (DRUG).
Who is sponsoring clinical trial NCT02661490?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02661490 being conducted?
This trial has 10 study locations across Alabama, Arizona, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Norovirus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02661490's enrollment target sits among peer trials
320 152nd of 2000 higher than 1,848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI